GSK launches OTC weight loss drug alli, orlistat in Europe

GlaxoSmithKline (GSK) has announced that alli – the first clinically proven over the counter weight loss aid – is available in pharmacies across Europe.

GSK has received a non-prescription licence for alli (orlistat 60mg); the first time the European Commission has approved a non-prescription product for weight loss.

The centrally approved marketing authorisation means GSK can introduce alli for adults with a BMI of 28 kg/m2 or more, in all 27 EU member countries.

Manfred Scheske, President GSK Consumer Healthcare Europe said, "alli offers adults a real opportunity for losing weight. alli has been well received by millions of people in the US and we are very excited about the number of people it could help across Europe achieve their goal to lose weight."

Clinical trials show that alli, when used in conjunction with a reduced calorie, lower-fat diet, can help people lose 50 per cent more weight than by dieting alone. So for every two kilos (pounds) lost by dieting alone, alli could help them lose one more. It works by stopping some of the fat you eat being absorbed into the body and turning into extra kilos (pounds).

alli is a new category within weight loss management which is supported by a multi-million pound investment in pharmacy training, consumer marketing and a behavioural support programme in countries throughout Europe. It will be distributed exclusively through pharmacies.

Users can benefit from the online alli programme, which provides tools and support to help them follow a sensible diet and become more active, encouraging sustainable weight loss.

alli is a registered trade mark of the GlaxoSmithKline group of companies.


(Editor compiled and published GSK launches OTC weight loss drug alli, orlistat in Europe at HealthNewsTrack on April 21, 2009 sourced from GlaxoSmithKline - http://gsk.com)

Weight loss - recent articles and current news stories:

- 10% weight loss in obesity with green coffee beans extract
- Weight loss increases libido in obese
- Low carb, higher fat diets cause no arterial health risks
- Weight loss between pregnancies lowers gestational diabetes GDM risk
- Weight loss may improve memory and concentration

Most related articles:

- GSK launches OTC weight loss drug alli, orlistat in Europe
- Weight loss drug orlistat may lead to liver injury - 20.3
- GSK's alli for weight loss approved in Europe - 16.8
- Counterfeit weight loss drug Alli containing sibutramine - 14
- Low carb diet effective at lowering blood pressure - 9.2

More related articles:

- Weight loss drug, Weight loss, Healthcare, Losing weight, Calorie, Lower fat diet, Dieting, Weight loss management, Obesity
- GSK's alli for weight loss approved in Europe - 24.1
- Weight loss increases libido in obese - 20.2
- Weight loss between pregnancies lowers gestational diabetes GDM risk - 19.8
- Worksite-based weight loss programs good for obese - 18.3

Weight loss related articles:

- Worksite-based weight loss programs good for obese - 5.3
- Weight loss between pregnancies lowers gestational diabetes GDM risk - 4.6
- Young You recalls weight loss pills - 4.4
- Weight loss caused by chewing gum - BMJ - 4.1

Weight loss article/news source:

Read more health articles from GlaxoSmithKline and health articles from USA.

Weight loss - search related terms:

Calorie, Dieting, Healthcare, Losing weight, Lower fat diet, Obesity, Weight loss, Weight loss drug, Weight loss management,
Weight loss books,

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
1.76